Skip to content

Gyre Therapeutics, Inc. GYRE Ratios & Valuation

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Gross margin95.1%-1.1pp95.4%-1.0pp95.5%-0.8pp95.9%-0.3pp96.2%+0.1pp
Operating margin-0.1%-10.4pp9.9%-5.4pp11.2%+83.7pp9.1%+69.7pp10.3%+67.2pp
EBITDA margin2.1%-9.8pp12%-4.8pp13.4%+84.5pp11.2%+70.7pp12%+67.8pp
Free cash flow margin2.6%-0.2%2.7%
Returns
Return on invested capital-0.1%-19.4pp12.8%16.7%13.7%19.3%
Efficiency
Asset turnover0.8×0.0×0.8×-0.1×0.8×-0.8×0.7×-0.9×0.8×-0.8×
Inventory turnover0.6×0.0×0.7×-0.1×0.6×0.6×0.6×
Liquidity
Current ratio4.6×+1.0×5.6×+2.3×6.2×+2.5×5.4×+2.0×3.6×+0.4×
Quick ratio4.1×+0.9×+2.0×5.6×+2.3×4.9×+1.8×3.2×+0.2×
Cash ratio1.9×+1.1×+1.4×2.5×+1.5×2.2×+1.1×0.8×-0.7×
Leverage
Debt-to-equity0.0×0.0×0.0×0.0×0.0×
Debt-to-assets0.0×0.0×0.0×0.0×0.0×
Net debt / EBITDA-14.8×-13.7×-2.6×-2.0×-2.7×-3.1×-1.1×
Per Share
Book value per share$1.11+66.0%$1.03+66.0%$0.98+59.3%$0.90+51.8%$0.67+21.0%
Valuation
Market capitalization$694.58M-4.7%$680.11M-34.5%$677.57M-42.2%$689.9M-32.4%$722.69M-51.6%
Enterprise value$657.9M-8.0%$643.98M-37.4%$638.33M-44.9%$654.8M-34.9%$709.23M-51.5%
Price / sales5.9×-1.3×5.8×-4.0×6.3×-4.8×6.8×-2.4×7.2×-5.7×
Price / book6.9×-3.8×6.4×-10.0×6.6×-11.9×7.5×-9.4×10.6×-15.7×
EV / EBITDA265.6×+206×46.1×-11.9×44.6×57.3×58.9×
EV / sales5.6×-1.5×5.5×-4.2×-5.1×6.4×-2.6×-5.6×
Free cash flow yield0.4%-0%0.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Gyre Therapeutics, Inc.'s profit margins?
Gyre Therapeutics, Inc. (GYRE) runs a 95.1% gross margin and a -0.1% operating margin, with a 6.3% net margin.
Where do Gyre Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Gyre Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.